Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Eric Jonasch MD

Eric Jonasch MD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. Eric Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, where he is also Co-Chair of the Renal Cancer Program. Since 2003, Dr. Jonasch has been the Director of the Von Hippel Lindau (VHL) Clinical Center in Houston. He performs clinical, translational, and basic research in VHL disease and kidney cancer.

After receiving his MDCM degree from McGill University Faculty of Medicine, Dr. Jonasch underwent clinical residency in internal medicine at the Royal Victoria Hospital in Montreal. Subsequently, he completed a clinical fellowship in Hematology/Oncology at the New England Medical Center in Boston, as well as a research fellowship. He was then awarded a research fellowship at the Beth Israel Deaconess Medical Center in Boston.

Dr. Jonasch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and is Vice Chair of the National Comprehensive Cancer Network kidney cancer guidelines. Additionally, Dr. Jonasch has published widely in many peer-reviewed journals and has contributed to and published various books.

Disclosures

  • Consultant: Aravive; Aveo; BMS (Bristol Myers Squibb); Calithera; Eisai; Exelixis; Ipsen; Merck; NiKang; Pfizer; Novartis AG
  • Research funding: Merck; NiKang; Novartis AG; Telix

Recent Contributions to PracticeUpdate:

  1. MK-6482 as a Potential Treatment for VHL Disease-Associated Clear Cell RCC
  2. HIF Activity Promotes Antitumor Effector Function and Tissue Residency by CD8+ T Cells
  3. Diversity, Equity and Inclusion and VHL
  4. Lenvatinib and Pembrolizumab Compared to Sunitinib for Advanced Renal Cell Carcinoma
  5. Management of VHL Patients in the Era of COVID-19
  6. Immune Checkpoint Inhibitors for RCC With Sarcomatoid Dedifferentiation
  7. Updated Results of a Trial of MK-6482 for Patients With Advanced Clear Cell RCC
  8. Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
  9. ASCO GU 2021: Recommendations From Dr. Eric Jonasch
  10. Approach to Renal Masses Among Patients With VHL Disease

Most Read This Week

Recently Updated